Individualized dupilumab therapy in the treatment of pediatric patients with severe atopic dermatitis: Case series in a Malaysian Tertiary Center

To look at patient characteristics, response to dupilumab, and adverse events due to treatment. This was a retrospective review of all pediatric patients on dupilumab and topical corticosteroids for severe atopic dermatitis in Paediatric Dermatology Clinic, Women and Children Hospital, Kuala Lumpur,...

Full description

Saved in:
Bibliographic Details
Main Authors: Wai Quen Lee (Author), Siti Nuraihan Nordin (Author), Sabeera Begum Kader Ibrahim (Author), Kin Fon Leong (Author)
Format: Book
Published: Wolters Kluwer Medknow Publications, 2022-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_263a51aad8cc4d56b77ed9ddeefdee4c
042 |a dc 
100 1 0 |a Wai Quen Lee  |e author 
700 1 0 |a Siti Nuraihan Nordin  |e author 
700 1 0 |a Sabeera Begum Kader Ibrahim  |e author 
700 1 0 |a Kin Fon Leong  |e author 
245 0 0 |a Individualized dupilumab therapy in the treatment of pediatric patients with severe atopic dermatitis: Case series in a Malaysian Tertiary Center 
260 |b Wolters Kluwer Medknow Publications,   |c 2022-01-01T00:00:00Z. 
500 |a 2319-7250 
500 |a 10.4103/ijpd.ijpd_177_21 
520 |a To look at patient characteristics, response to dupilumab, and adverse events due to treatment. This was a retrospective review of all pediatric patients on dupilumab and topical corticosteroids for severe atopic dermatitis in Paediatric Dermatology Clinic, Women and Children Hospital, Kuala Lumpur, from 2020 to 2021. In this cohort, 50% achieved Eczema area and severity index (EASI) -75 by week 12, 25% at week 16, and 25% at week 56. Three of four patients achieved EASI-75 at a median of 12 weeks of treatment, despite not receiving loading doses of dupilumab. None of our patients had conjunctivitis or upper respiratory tract infection while treated with dupilumab. In conclusion, dupilumab is a safe and effective drug to induce remission in severe pediatric eczema, without undesirable side effects in our cohort. In a resource-limited setting, individualized treatment regimen without loading doses is as effective as fixed-dose regimens with loading doses to achieve EASI-75. 
546 |a EN 
690 |a atopic dermatitis 
690 |a case series 
690 |a dupilumab 
690 |a pediatric 
690 |a Dermatology 
690 |a RL1-803 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Indian Journal of Paediatric Dermatology, Vol 23, Iss 4, Pp 309-313 (2022) 
787 0 |n http://www.ijpd.in/article.asp?issn=2319-7250;year=2022;volume=23;issue=4;spage=309;epage=313;aulast=Lee 
787 0 |n https://doaj.org/toc/2319-7250 
856 4 1 |u https://doaj.org/article/263a51aad8cc4d56b77ed9ddeefdee4c  |z Connect to this object online.